CompletedPHASE1, PHASE2NCT02472054

Treatment of Familiar Lymphohistiocytosis

Studying Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Assistance Publique - Hôpitaux de Paris
Principal Investigator
Alain FISCHER, MD, PhD
Assistance Publique - Hôpitaux de Paris
Intervention
Alemtuzumab(drug)
Enrollment
29 enrolled
Eligibility
17 years · All sexes
Timeline
20152020

Study locations (1)

Collaborators

URC-CIC Paris Descartes Necker Cochin

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02472054 on ClinicalTrials.gov

Other trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Additional recruiting or active studies for the same condition.

See all trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

← Back to all trials